KLRC1 and lymphoma: Indeed, antibody mediated blockade of NKG2A:HLA-E interactions has been shown to activate NK cells in vitro and in vivo against both lymphoma and solid tumor cells (15) and the blocking anti-NKG2A antibody monolizumab is currently in phase 3 clinical trials for Head and Neck cancer in combination with the anti-EGFR antibody cetuximab (NCT04590963).